Style | Citing Format |
---|---|
MLA | Arjmandi K, et al.. "Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer." Journal of Pathology and Translational Medicine, vol. 59, no. 2, 2025, pp. 105-114. |
APA | Arjmandi K, Salahshourifar I, Irani S, Ameli F, Esfandbod M (2025). Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer. Journal of Pathology and Translational Medicine, 59(2), 105-114. |
Chicago | Arjmandi K, Salahshourifar I, Irani S, Ameli F, Esfandbod M. "Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer." Journal of Pathology and Translational Medicine 59, no. 2 (2025): 105-114. |
Harvard | Arjmandi K et al. (2025) 'Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer', Journal of Pathology and Translational Medicine, 59(2), pp. 105-114. |
Vancouver | Arjmandi K, Salahshourifar I, Irani S, Ameli F, Esfandbod M. Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer. Journal of Pathology and Translational Medicine. 2025;59(2):105-114. |
BibTex | @article{ author = {Arjmandi K and Salahshourifar I and Irani S and Ameli F and Esfandbod M}, title = {Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer}, journal = {Journal of Pathology and Translational Medicine}, volume = {59}, number = {2}, pages = {105-114}, year = {2025} } |
RIS | TY - JOUR AU - Arjmandi K AU - Salahshourifar I AU - Irani S AU - Ameli F AU - Esfandbod M TI - Association Study of Tyms Gene Expression With Tyms and Enosf1 Genetic Variants in Neoadjuvant Chemotherapy Response of Gastric Cancer JO - Journal of Pathology and Translational Medicine VL - 59 IS - 2 SP - 105 EP - 114 PY - 2025 ER - |